This grant focuses on Alzheimer's disease (AD), the most frequent neurodegenerative condition, and on the question of how elevation of amyloid-beta (A-beta) levels in the brain contributes to its pathogenesis. Recently, we discovered that exploration of a novel environment causes putative DNA double strand breaks (DSBs) in neurons of wildtype (WT) mice. The DSBs were most abundant in memory centers and were repaired within 24 hours. Transgenic mice with neuronal expression of familial AD-mutant forms of the human amyloid precursor protein (hAPPFAD mice), which simulate several aspects of AD, had increased neuronal DSBs at baseline and more severe and prolonged DSBs after exploration. Treatment with the anti-epileptic drug levetiracetam suppressed aberrant network activity, normalized levels of DSBs and improved synaptic functions as well as learning and memory in hAPPFAD mice. In primary neuronal cultures from WT mice, exposure to human A-beta oligomers increased DSBs, and this effect was prevented by blocking NR2B-containing NMDA-type glutamate receptors. Thus, A-beta may exacerbate and prolong activity-related increases in neuronal DSBs, possibly as a result of synaptic and network dysfunction. By changing the expression of genes involved in cognitive functions and the regulation of neuronal activities, this process could promote a vicious cycle and contribute to the pathogenesis of AD. To test these hypotheses, we will (1) further characterize the nature and causes of neuronal DSBs in WT and hAPP-J20 mice, (2) determine the mechanisms by which levetiracetam counteracts A-beta-induced increases in neuronal DSBs, (3) determine whether neuronal DSBs and the associated histone variant YH2A.X specifically affect learning/memory and related gene expression, and (4) validate key findings in other mouse models and in humans with AD. The most novel aspects of this proposal include the hypotheses that physiological brain activity causes transient neuronal DSBs that DNA integrity in neurons is regulated by the activity of NR2B-containing glutamate receptors, and that pathologically elevated levels of A-beta alter these processes by changing the activities of synapses and neuronal networks. Innovative approaches include the use of chromatin immunoprecipitation and massively parallel DNA sequencing to identify the genes affected and the use of a novel APP knockin mouse that overproduces A? but not APP. Investigational anti-A-beta treatments have been associated with serious side effects that were probably unrelated to the reduction of A-beta levels per se. It is therefore desirable to identify alternative or complementary therapeutic strategies to make the brain more resistant to A-beta-induced neuronal dysfunction. Protecting the neuronal genome against A-beta's adverse effects could be particularly critical in this regard.

Public Health Relevance

Amyloid-beta (A-beta) peptides and neuronal DNA damage may causally contribute to Alzheimer's disease (AD), the major cause of dementia in the elderly. Because investigational anti-A-beta treatments have been associated with serious side effects, it is desirable to identify alternative or complementary strategies to make the brain more resistant to A-beta-induced neuronal dysfunction. The current proposal aims to elucidate the relationship between A-beta-induced DNA damage and neuronal dysfunction, to block the disease-causing processes involved, and to normalize the expression of genes required for effective learning and memory.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG011385-20
Application #
8665337
Study Section
Special Emphasis Panel (ZRG1-MDCN-G (91))
Program Officer
Petanceska, Suzana
Project Start
1992-09-01
Project End
2018-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
20
Fiscal Year
2014
Total Cost
$452,312
Indirect Cost
$191,099
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Ettle, Benjamin; Reiprich, Simone; Deusser, Janina et al. (2014) Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci 62:68-78
Games, Dora; Valera, Elvira; Spencer, Brian et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 34:9441-54
Games, Dora; Seubert, Peter; Rockenstein, Edward et al. (2013) Axonopathy in an ýý-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated ýý-synuclein. Am J Pathol 182:940-53
Suberbielle, Elsa; Sanchez, Pascal E; Kravitz, Alexxai V et al. (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-ýý. Nat Neurosci 16:613-21
Borlikova, Gilyana G; Trejo, Margarita; Mably, Alexandra J et al. (2013) Alzheimer brain-derived amyloid ýý-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 34:1315-27
Morris, Meaghan; Koyama, Akihiko; Masliah, Eliezer et al. (2011) Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One 6:e29257
Lee, Seung-Jae; Lim, Hee-Sun; Masliah, Eliezer et al. (2011) Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70:339-48
Cisse, Moustapha; Halabisky, Brian; Harris, Julie et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469:47-52
Crews, L; Patrick, C; Adame, A et al. (2011) Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Dis 2:e120
Cisse, Moustapha; Sanchez, Pascal E; Kim, Daniel H et al. (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 31:10427-31

Showing the most recent 10 out of 70 publications